Browse the evidence

The use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes.

Healthcare providers should be cautious when prescribing semaglutide to patients with a history of AOM use, as they may not achieve optimal weight loss.

Tirzepatide dose-dependently reduced voluntary alcohol consumption and prevented binge and relapse-like drinking.

Tirzepatide may help in managing alcohol use disorder by reducing consumption and preventing relapse.

Tirzepatide affected metabolic parameters including body weight, adipose tissue mass, hepatic triglycerides, and circulating pro-inflammatory cytokines.

Tirzepatide may have beneficial effects on metabolic health in addition to its impact on alcohol consumption.

There is a need for a dedicated trial to examine the benefits of semaglutide in type 1 diabetes.

Further research is warranted to validate the effects of semaglutide in type 1 diabetes.

Tirzepatide has a generally safe profile with possible mild-to-moderate gastrointestinal side effects.

Healthcare providers should monitor patients for gastrointestinal side effects when prescribing tirzepatide.

Neither chia flour nor whey protein supplementation elicited an enhanced effect on fat-free mass (FFM) and strength gains after an 8-week resistance training program.

Supplementing with chia flour or whey protein does not provide additional benefits for body composition or strength in young men already consuming a high protein diet.

Global consumption of ultra-processed foods (UPFs) has increased dramatically.

Practitioners should be aware of the rising trend in UPF consumption.

The HIFEM+RF procedure is reported to be safe and effective, with high patient satisfaction and comfort.

Practitioners can expect high patient satisfaction and comfort with the HIFEM+RF procedure.

No additional benefits were observed for ∑MT.

Practitioners should note that increasing volume may not benefit all measures of training outcomes.

There are inadequacies in the measures used to qualify obesity.

Practitioners should be aware of the limitations in current obesity measures when assessing health risks.

There is a need to determine intermediate factors and mechanisms connecting excess adiposity and health.

Identifying these factors can enhance targeted interventions for obesity-related health issues.

GLP-1 medicines may contribute to decreased cancer incidence.

Consider the potential cancer risk reduction when prescribing GLP-1 medicines.

No significant associations were found between white rice intake and risk of cardiovascular diseases, CVD mortality, cancer, and metabolic syndrome.

Practitioners can inform patients that white rice does not appear to significantly impact these other health risks.

Friedreich's ataxia (FRDA) individuals exhibit higher postprandial insulin secretion (insulin secretory rate incremental area under the curve 30-180 minutes, 24,652 vs 17,858, P < .05) compared to controls.

Higher insulin secretion in FRDA may be a compensatory mechanism for lower insulin sensitivity.

Lower mitochondrial oxidative phosphorylation (OXPHOS) capacity and inactivity contribute to lower insulin sensitivity in individuals with Friedreich's ataxia (FRDA).

Improving mitochondrial function and physical activity may enhance insulin sensitivity in FRDA patients.

Gastrointestinal side effects were most common, with Semaglutide showing the highest incidence.

Clinicians should be aware of the potential for gastrointestinal side effects, particularly with Semaglutide.

GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591, P < 0.001) and intussusception (HR 1.383, P = 0.025) compared with oral antidiabetic therapy.

Clinicians should monitor patients on GLP-1 RAs for signs of gastroparesis and intussusception.

Both semaglutide and tirzepatide show gastrointestinal side effects including nausea, vomiting, pancreatitis, and diarrhea.

Clinicians should be aware of these common gastrointestinal side effects when prescribing these medications.

Tirzepatide is preferred over semaglutide due to less reported side effects and enhanced benefits in promoting bone formation.

Tirzepatide may be a better option for patients needing obesity management with fewer side effects.

GLP-1 receptor agonists reduced systolic blood pressure (SBP) by 3.4 mmHg and diastolic blood pressure (DBP) by 0.9 mmHg.

GLP-1 receptor agonists can be considered for managing blood pressure in overweight or obese patients.

Incretin-based therapy did not increase the risk of hypoglycaemia or pancreatitis.

Clinicians can consider incretin-based therapies as safe options for managing obesity and hypertension without increasing hypoglycaemia or pancreatitis risk.

Rational protein engineering and delivery innovations transformed incretin biology into global metabolic therapeutics.

Innovations in protein engineering can enhance therapeutic efficacy.

The balance between adipose tissue reduction and lean mass preservation with GLP-1RAs remains incompletely understood in clinical settings.

Further research is needed to clarify the effects of GLP-1RAs on body composition in clinical practice.

Obesity is associated with increased risk of cancer, accounting for approximately 10% of new cancer diagnoses annually in the US.

Healthcare practitioners should consider obesity as a significant risk factor for cancer in their patients.